Top of this page
Skip navigation, go straight to the content

Investors UCB equity story

Since 2015, UCB has embarked on a very important change journey:

the Patient Value Strategy

In 2019 we entered the next phase of our Patient Value Strategy:

“Accelerate & Expand” (2019-2022)

 

 
During this phase, we are accelerating our growth potential by further improving our ability to demonstrate differentiation of our medicines, by accelerating our development timelines through new approaches and by improving patients’ access to our key medicines.

The evolving COVID-19 pandemic is profoundly impacting our lives, and places tremendous strain on healthcare systems and society at large. Since the start of the crisis, UCB has taken measures to protect our colleagues around the world, to stand by patients, to help our communities and take our part in the global response to the pandemic. We know that it is our responsibility to help where we can make an impact. Find out what actions UCB has taken here.

"Accelerate & Expand" (2019-2021)

Making significant progress towards this ambitious goal...

Focus on patients

     

Briviact  

 

2 recent launches

Evenity      Nayzilam

Strengthen R&D

bimekizumab positive Phase 3 results in psoriasis

zilucoplan

Staccato® alprazolam

 

new Phase 3 programs

bimekizumab in psoriatic arthritis, axial spondyloarthritis  & hidradenitis suppurativa

rozanolixizumab in myasthenia gravis & immune thrombocytopenia

dapirolizumab pegol  in lupus

identify & act on opprotunities

Ra Pharma   Engage

Ferring     Handl THerapeutics

 
  • infleXio: new biotech manufacturing plant (Belgium)
  • Divestiture: Niferex® (China) & alprostadil

 

 
 

2019 achievements

  • Evenity® (romosozumab) and Nayzilam® (midazolam) were approved and launched as planned.
  • bimekizumab delivered three positive Phase 3 study results in psoriasis; submission to regulatory bodies should occur  mid-2020.
  • UCB started multiple Phase 3 studies: bimekizumab in psoriatic arthritis, axial spondyloarthitis and hidradenitis suppurativa (early 2020), padsevonil in drug resistant epilepsy and rozanolixizumab in generalized myasthenia gravis as well as in immune thrombocytopenia.
  • UCB0107, our anti-Tau antibody, reported positive Phase 1 results and will enter the confirmatory study.

2020 so far...

  • rozanolixizumab Phase 3 started in ITP, Immune ThrombocytoPenia (Jan)  
  • bimekizumab Phase 3 was initiated in a 4th indication: hidradenitis suppurativa (Feb)  
  • padsevonil Phase 2b reported topline results (Mar)  
  • UCB finalized the acquisition of Ra Pharma (Apr)  
  • UCB acquired Engage Therapeutics & Staccato® Alprazolam (Jun)
  • bimekizumab Phase 3 data (BE VIVID & BE READY studies) in psoriasis presented at AAD (Jun)
  • UCB and Ferring Pharmaceuticals Inc. entered into a co-promotion agreement to commercialize the prefilled syringe formulation Cimzia®  in the U.S. for the treatment of Crohn’s disease (Jul).
  • bimekizumab positive Phase 3b topline results (BE RADIANT study) in psoriasis (Jul)
  • UCB enters into collaboration with Roche to develop UCB0107 in with Alzheimer’s disease (Jul)
  • bimekizumab filing in psoriasis (U.S. & EU - Sept)
  • bimekizumab Phase 3 data (BE  SURE study) in psoriasis presented at EADV (Oct)
  • UCB acquired Handl Therapeutics & signed new R&D collaboration with Lacerta Therapeutics (Nov)
  • Vimpat® approval in epilepsy PGTCS (U.S. - Nov)
 

Our key medicines

We bring solutions to people living with neurological or immunological diseases.

Serving patients, our key medicines continued their growth in 2019.

Immunology

Cimzia

Peak sales guidance

 

  • Cimzia® > € 2 billion by 2024  
  • Vimpat® > € 1.5 billion by 2022  
  • Briviact® > € 600 million by 2026
  • Neupro® ~ current level  
 
Keppra® reached peak sales of € 1.2 billion in 2008.

Neurology

Vimpat

 

Keppra logo

Neupro

 
 

Our pipeline

In a challenging environment, our pipeline builds the basis of UCB’s sustainable long term growth.

To create a pipeline that will make a real difference in people’s lives, we focus on our key assets: our expertise in small and large molecules and our expertise in the fields of neurology and auto-immune diseases.

Late stage clinical pipeline to deliver patient value

  • Bimekizumab in psoriasis, psoriatic arthritis, axial spondyloarthritis and hidradenitis suppurativa
  • Zilucoplan in general Myasthenia Gravis
  • Rozanolixizumab in Immune ThrombocytoPenia, Myasthenia Gravis, Chronic Inflammatory Demyelinating Polyneuropathy 
  • Dapirolizumab pegol in systemic lupus erythematosus (in partnership with Biogen)
  • Staccato® alprazolam in acute epileptic seizure
  • UCB0107 (anti-Tau) in progressive supranuclear palsy
 

Clinical studies index

UCB is committed to sharing information on studies and making study results publicly accessible. You will find below links to the clinical studies (Phase 2-4) of our main R&D projects.

More information about our clinical studies index and our position paper are available here.

Pipeline - status September 2020

September 2020

IMNM: Immune-Mediated Necrotizing Myopathy  

CIDP: Chronic Inflammatory Demyelinating Polyneuropathy

* In partnership with Biogen

Zilucoplan in COVID-associated ARDS by University of Ghent (Belgium) & Medical Research Council (U.K.)

Zilucoplan in amyotrophic lateral sclerosis (ALS) by HEALEY ALS Platform Trial

 

 

 

Questions?

Contact the IR team and we will do our best to help you!